A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)

• Status: Not yet recruiting
• Trial end date: 2021-05-30
• Target enrollment: 500
• Participant gender: All

Summary

Objective To determine the efficacy and safety of arbidol in patients with 2019 Novel Coronavirus (2019-nCoV).Methods Patients with 2019-nCoV were divided into three groups according to randomized double-blinded controlled clinical trial principle.Patients in three groups were administrated with arbidol,200mg,tid or arbidol,400 mg,tid or not for 5 days respectively. Other antiviral and comprehensive treatments of the three groups of patients are consistent. Then investigators will compare the first outcome: 28-day mortality, and secondary outcome: ICU hospitalization time, mechanical ventilation time, Hospitalization costs, antibiotic use costs, SOFA scores, CURB-65 scores, APACHE scores, and other clinical indicators.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiangya Hospital of Central South University

Criteria

Inclusion Criteria:

Patients diagnosed with RT-PCR for 2019 Novel Coronavirus (2019-nCoV)

Exclusion Criteria:

Patients infected with other viruses